Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

NCT04038970 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

145

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL: KN019, 5mg/kg
BIOLOGICAL: KN019, 10 mg/kg
BIOLOGICAL: Placebo
COMBINATION_PRODUCT: Methotrexate

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd